Quarterly ResultMay 7, 2026, 06:46 AM
InfuSystem Q1 Net Income $1.0M; Revenue $33.7M (-3%)
AI Summary
InfuSystem Holdings, Inc. reported first-quarter 2026 financial results, achieving a net income of $1.0 million, a significant improvement from a net loss of $0.3 million in the prior year. Net revenues decreased 3% to $33.7 million, primarily due to a strategic restructuring of a biomedical services contract, which management states improved overall profitability. Adjusted EBITDA remained flat at $6.4 million, with an expanded margin of 18.9%. The company reaffirmed its full-year 2026 guidance, anticipating pro-forma net revenue growth of 6% to 8%.
Key Highlights
- Net income was $1.0 million ($0.05 per diluted share) vs. a net loss of $0.3 million in Q1 2025.
- Net revenues decreased 3% to $33.7 million; pro-forma net revenue grew 1.7% after adjustments.
- Adjusted EBITDA was $6.4 million, flat YoY, with an Adjusted EBITDA margin of 18.9% (up 0.7%).
- Patient Services net revenue increased 6% to $22.1 million, driven by Oncology and Wound Care.
- Wound care net revenue more than doubled to $2.1 million, now 6% of total revenue.
- Device Solutions net revenue decreased 17% to $11.6 million due to contract restructuring.
- Gross profit increased 3% to $19.7 million, with gross margin expanding to 58.4%.
- Reaffirmed full-year 2026 guidance for pro-forma net revenue growth of 6-8% and mid-to-low 20s Adjusted EBITDA margin.